Compare NSYS & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSYS | LITS |
|---|---|---|
| Founded | 1981 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.1M | 36.3M |
| IPO Year | 1996 | 2003 |
| Metric | NSYS | LITS |
|---|---|---|
| Price | $10.65 | $0.90 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.4K | ★ 248.1K |
| Earning Date | 11-12-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.85 | 13.81 |
| EPS | 0.09 | ★ 0.48 |
| Revenue | ★ $14,371,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $120.11 | ★ $2.04 |
| Revenue Growth | ★ 7.01 | N/A |
| 52 Week Low | $6.74 | $0.69 |
| 52 Week High | $18.01 | $2.08 |
| Indicator | NSYS | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 51.27 | 37.10 |
| Support Level | $9.91 | $0.74 |
| Resistance Level | $12.33 | $1.05 |
| Average True Range (ATR) | 0.67 | 0.09 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 31.85 | 3.45 |
Nortech Systems Inc is a United States-based electronic manufacturing services company. It offers value-added engineering, technical, and manufacturing services and support, including project management, design, testing, prototyping, manufacturing, supply chain management, and post-market services. The company's manufacturing and engineering services include complete medical devices, printed circuit board assemblies, wire and cable assemblies, and complex higher-level electro-mechanical assemblies. It operates in the Medical, Aerospace, Defense, and Industrial markets, with key revenue coming from medical-related markets.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients. The company operates in the segments: Digital Asset Treasury Strategy and Development of Pharmaceutical Products.